Pricing Log in Create free account
Friday 6 November 2026 Export TXG’s income statement to Excel — free account

10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue
+1.12%
EPS
+31.8%
Free cash flow
−4.61%

Quarter to September 2026, against a year earlier

59.18 1.12 +1.93%
Market cap
$7.6B
P/E
0.0×
Fwd P/E
−95.9×
Dividend yield
—
F-score
6/9
Altman Z
3.99
Beneish M
−3.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

10x Genomics 10-Q filed Aug 7, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 5:31 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 8, 2025: 21 added · 17 removed · 17 modified; 1 with only figures updated; 2 moved without change